



## Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Abdul Rafeh Naqash<sup>1,7</sup> · Biagio Ricciuti<sup>2,3</sup> · Dwight H. Owen<sup>4</sup> · Vaia Florou<sup>5,10</sup> · Yukihiro Toi<sup>6</sup> · Cynthia Cherry<sup>1,7</sup> · Maida Hafiz<sup>8</sup> · Andrea De Giglio<sup>2</sup> · Mavish Muzaffar<sup>7</sup> · Sandip H. Patel<sup>4</sup> · Shunichi Sugawara<sup>6</sup> · Jarred Burkart<sup>4</sup> · Wungki Park<sup>5,9</sup> · Rita Chiari<sup>2</sup> · Jun Sugisaka<sup>6</sup> · Gregory A. Otterson<sup>4</sup> · Gilberto de Lima Lopes<sup>5</sup> · Paul R. Walker<sup>7</sup>

Published online: 28 April 2020

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2020

**Correction to: Cancer Immunology, Immunotherapy**  
<https://doi.org/10.1007/s00262-020-02536-5>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article unfortunately contained a mistake. The second sentence of the section “irAEs and ICI efficacy” should read as

Patients with irAEs had a higher objective response rate (ORR) compared with patients with no-irAEs 40.1% (4.9% CR + 35.2% PR) versus 14.1% [(2.1% CR + 12.1% PR);  $p < 0.01$ ].

---

The original article can be found online at <https://doi.org/10.1007/s00262-020-02536-5>.

---

✉ Abdul Rafeh Naqash  
[abdulrafeh.naqash@nih.gov](mailto:abdulrafeh.naqash@nih.gov); [rafehnaqash@hotmail.com](mailto:rafehnaqash@hotmail.com)

<sup>1</sup> Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Clinic, National Cancer Institute, Bldg 31/3A44, 31 Centre Drive, Bethesda, MD 20892, USA

<sup>2</sup> Thoracic Oncology Unit, Santa Maria Della Misericordia Hospital, University of Perugia, Perugia, Italy

<sup>3</sup> Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

<sup>4</sup> Division of Medical Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH, USA

<sup>5</sup> Division of Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA

<sup>6</sup> Department of Pulmonary Medicine, Sendai Kousei Hospital, Hirosemachi, Aoba-Ku, Sendai, Japan

<sup>7</sup> Division of Hematology/Oncology, Department of Internal Medicine, East Carolina University, Greenville, NC, USA

<sup>8</sup> Department of Pulmonary Medicine, East Carolina University, Greenville, NC, USA

<sup>9</sup> Memorial Sloan Kettering Cancer Center, New York, USA

<sup>10</sup> Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA